clinical trial · NCT05366868
Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus
National Center for Global Health and Medicine, Japan·phase4·active not recruiting·n = 567
Diabetes Mellitus, Type 2ImegliminMetforminVildagliptin
brief summary
Study subjects will be randomly assigned to the three groups and receive the study drug for maximum of 156 weeks and undergo blood samplings and other diabetes mellitus-related tests. The aim of the present study is to evaluate the durability of glycemic control over 3 years for patients with type 2 diabetes on diet and exercise therapy treated with oral hypoglycemic drug monotherapy.
started
May 26, 2022
primary completion
Aug 31, 2026
completion
Mar 31, 2027
last updated
Apr 9, 2026
official title
Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus: a Multicenter, Open-label, Randomized, Controlled Trial (DIGNITY Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol